These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29866876)

  • 1. Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.
    Thwaites M; Hall D; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
    Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
    J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.
    Thwaites M; Hall D; Stoneburner A; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Diagn Microbiol Infect Dis; 2018 Dec; 92(4):338-345. PubMed ID: 30097297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.
    Galani I; Souli M; Daikos GL; Chrysouli Z; Poulakou G; Psichogiou M; Panagea T; Argyropoulou A; Stefanou I; Plakias G; Giamarellou H; Petrikkos G
    J Chemother; 2012 Aug; 24(4):191-4. PubMed ID: 23040681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.
    Clark JA; Kulengowski B; Burgess DS
    Diagn Microbiol Infect Dis; 2020 Oct; 98(2):115117. PubMed ID: 32755805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
    Almaghrabi R; Clancy CJ; Doi Y; Hao B; Chen L; Shields RK; Press EG; Iovine NM; Townsend BM; Wagener MM; Kreiswirth B; Nguyen MH
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4443-51. PubMed ID: 24867988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
    Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
    J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
    Zhang Y; Kashikar A; Bush K
    J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.
    Haidar G; Alkroud A; Cheng S; Churilla TM; Churilla BM; Shields RK; Doi Y; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5208-14. PubMed ID: 27297487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
    Galani I; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Souli M;
    BMC Infect Dis; 2019 Feb; 19(1):167. PubMed ID: 30770727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
    Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
    Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City.
    Landman D; Babu E; Shah N; Kelly P; Bäcker M; Bratu S; Quale J
    J Antimicrob Chemother; 2010 Oct; 65(10):2123-7. PubMed ID: 20667885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; Kim A; Krause KM; MacGowan AP
    Int J Antimicrob Agents; 2019 Nov; 54(5):626-632. PubMed ID: 31299297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in Gram-negative organisms derived from whole-genome sequencing.
    Pragasam AK; Jennifer SL; Solaimalai D; Muthuirulandi Sethuvel DP; Rachel T; Elangovan D; Vasudevan K; Gunasekaran K; Veeraraghavan B
    Indian J Med Microbiol; 2020; 38(3 & 4):313-318. PubMed ID: 33154241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
    Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
    Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.
    Livermore DM; Mushtaq S; Warner M; Zhang JC; Maharjan S; Doumith M; Woodford N
    J Antimicrob Chemother; 2011 Jan; 66(1):48-53. PubMed ID: 21078604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro bactericidal activity of aminoglycosides, including the next-generation drug plazomicin, against Brucella spp.
    Olsen SC; Carlson SA
    Int J Antimicrob Agents; 2015 Jan; 45(1):76-8. PubMed ID: 25459738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
    J Antimicrob Chemother; 2021 Jul; 76(8):2061-2070. PubMed ID: 34097032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of synergistic activity of plazomicin-based combinations against KPC-producing
    Iannaccone M; Boattini M; Bianco G; Cavallo R; Costa C
    J Chemother; 2022 Feb; 34(1):71-72. PubMed ID: 34187344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.